For independent reference labs
The Doc Lab Head Start Program
A path forward for independent reference laboratories facing reimbursement pressure on PCR-based UTI testing.
Independent reference laboratories facing reimbursement cuts on PCR-based UTI testing have a clear path forward with Doc Lab's Head Start Program. As reimbursement pressure mounts and payers demand evidence of clinical utility, most PCR UTI platforms leave labs without the documentation needed to defend their claims. Doc Lab is the first manufacturer with an investigator-blinded prospective clinical trial establishing both clinical utility and validity for its PCR UTI testing solution, the standard of evidence payers and auditors increasingly require. The Head Start Program is built specifically for reference labs ready to transition to a platform that can help you withstand scrutiny, with the clinical data already in hand. Labs that move now position themselves ahead of the next wave of reimbursement challenges rather than scrambling to respond to them.
What the Head Start Program Offers
-
Evidence payers ask for
An investigator-blinded prospective clinical trial establishing both clinical utility and validity — the standard of evidence payers and auditors increasingly require.
-
Reagents we manufacture
Our PCR UTI reagents are formulated and produced by Doc Lab, which means quality control from chemistry to result and technical support from the people who made it.
-
Keep processing physician office specimens
Contract with us for the technology and platform, and continue accepting and processing specimens from the practices you already serve.
Head Start Program
Move Before the Next Wave
If reimbursement pressure on PCR UTI testing is affecting your laboratory, let's talk about what transitioning to the Head Start Platform would look like.